FDA clears Tandem Mobi for up to seven days of tubeless wear
FDA has cleared the Tandem Mobi insulin pump for tubeless wear of up to seven days, with full US launch of the new set planned for H1 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The U.S. Food and Drug Administration has approved the Tandem Mobi insulin pump for a tubeless configuration that can be worn for as long as seven days, Tandem Diabetes Care said in a statement. Reuters also reported the decision.
The change comes through a new cartridge and infusion set that turn the current pump into a tubeless device, while the tubed option remains available. Full commercial rollout of these components in the United States is slated for the first half of 2027. Existing Tandem Mobi pumps work with the new parts, so customers with a valid warranty will not need to buy a new device. Sales will run only through pharmacies, and the company estimates that such coverage currently reaches roughly half of insured Americans.
why it matters
For Tandem, the clearance broadens its pump lineup and gives the company a new product in the insulin delivery segment. Revenue from the tubeless format will not arrive until the 2027 launch, however, and the pace of uptake will depend on wider pharmacy coverage.
market impact
Tandem Diabetes Care shares: a wider pump lineup supports the company's outlook
- Tandem Diabetes Care shares pressure up — the clearance widens the product lineup, but revenue arrives only after the 2027 launch
tags
instruments
sources
- Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear — TradingView, 13 November 2026 at 13:30 UTC
- Tandem Diabetes Care - FDA Clears Tandem Mobi As World's First Tubless AID System With Up To 7 Days Of Wear — Reuters, 13 November 2026 at 14:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗